Daniel Claassen, MD, MS

Daniel
Claassen
MD, MS
Division Chief
Behavioral and Cognitive Neurology
Professor
Neurology

Dr. Daniel Claassen is a Professor of Neurology at Vanderbilt University Medical Center, with subspecialty training in movement and cognitive neuroscience. He specializes in the diagnosis and treatment of neurodegenerative disorders characterized by disruptions to cognition, behavior, and movement. He is the chief of the Behavioral and Cognitive Neurology Division.

The theme of my work is to understand the biologic basis of how humans regulate of behavior, and the cognitive processes intrinsic to this nature. My research efforts are focused in patients that suffer from neurodegenerative conditions, and my current studies assess therapeutic outcomes in various neurodegenerative disorders, such as Parkinson, Huntington, and atypical Parkinsonian disorders (PSP and MSA). I also lead a basic research lab which investigates the neurobiological basis neurodegeneration through innovative cognitive neuroscience, neuroimaging tools, and biomarker discovery using patient biofluids. 

For more on Dr. Claassen’s current research, visit the Cognition and Movement Lab page.

Dane M. Chetkovich, MD, PhD

Dane
M.
Chetkovich
MD, PhD
Chair
Department of Neurology
Margaret and John Warner Chair
Neurological Education

Dr. Dane Chetkovich joined the Vanderbilt faculty as the Margaret and John Warner Professor and Chair of the Department of Neurology in 2017. Dr. Chetkovich is a frequently invited speaker at universities and meetings around the country and around the world. He has served on numerous review boards and committees, has participated in a number of study sections and is a member of the American Board of Psychiatry and Neurology committee responsible for writing the certification exam that is required for neurologists to become board-certified in the United States. Dr. Chetkovich is a general neurologist who is licensed to practice medicine in Tennessee, and he has been board-certified by the American Board of Psychiatry and Neurology since 2000.

Dr. Chetkovich has been the recipient of numerous awards and honors, including the Derek Denny-Brown Young Neurological Scholar Award by the American Neurological Association in 2010. He has also received several teaching awards including the John A. Kessler Teaching Award in 2016 and Neurology Resident Teaching Award in 2015.

Dr. Chetkovich earned a BA in Biochemistry and BS in Zoology in 1988 from the University of Texas at Austin. He attended Baylor College of Medicine in Houston, Texas, where he earned a PhD in Neuroscience in 1992 and MD in 1994. He completed an internship at Baylor followed by residency at University of California, San Francisco where he served as chief resident in Neurology and completed a postdoctoral fellowship in 2002. He served at Northwestern University Feinberg School of Medicine in Chicago for fifteen years where he was professor of Neurology and Physiology and director of the Medical Scientist Training Program.

Dr. Chetkovich’s research laboratory is focused on the molecular mechanisms that underlie the targeting of ion channels to synapses and other specialized areas of neurons. In particular, Dr. Chetkovich’s laboratory a multi-faceted approach, including electrophysiological, biochemical, molecular biology tools and gene therapy regulation of voltage-gated ion channels and how regulation of these channels may play a role in neuropsychiatric diseases such as epilepsy, autism and major depressive disorder.

David Charles, MD, Professor and Vice-Chair

David
Charles
MD
Vice Chair
Business Development & Strategy
Professor
Neurology
Medical Director
Vanderbilt Telehealth

Dr. Charles is Professor and Vice-Chair of Neurology and Medical Director, Vanderbilt Telehealth. His research interests include the treatment of spasticity and cervical dystonia and he is currently leading the only clinical trial approved by the United States Food and Drug Administration to test deep brain stimulation in people with early stage Parkinson's disease. 

Dr. Charles is a member of the American Neurological Association, Fellow of the American Academy of Neurology, and Chair of the Alliance for Patient Access. He is a member of Alpha Omega Alpha honor medical society and in 2007 received the CANDLE Award. Recipients are chosen based upon their positive impact on the lives of physicians-in-training and are recognized by their students as examples of excellence in medical education. From 1997-98, Dr. Charles served as a Health Policy Fellow in the United States Senate on the staff of the Labor Subcommittee for Public Health and Safety. In 1998 he studied deep brain stimulation for the treatment of movement disorders as a Fulbright Senior Scholar at the Universitaire de Grenoble in Grenoble, France. In 2000 Dr. Charles was a nominee for the United States House of Representatives from Tennessee’s Sixth Congressional District.

Dr. Charles graduated from Vanderbilt University School of Engineering in 1986 with a B.S. cum laude in Computer Science and Mathematics and earned his medical degree from Vanderbilt University School of Medicine in 1990. He did his internship in the department of Medicine and his residency in the department of Neurology at Vanderbilt. From 1993-94 he was Chief Resident in Neurology, and from 1994-95 he was a Fellow in Movement Disorders and Clinical Neurophysiology at Vanderbilt. In 1996, he completed a Health Care Management course at Vanderbilt’s Owen Graduate School of Management, and in 1997 he completed the Harvard Macy Institute Program for Physician Educators at Harvard Medical School.

Dr. Charles’ clinical research group’s focus is on improving the treatment of movement disorders, with specific interests in early stage Parkinson’s disease, Spasticity, and Cervical Dystonia. It undertakes patient-oriented research in a variety of care settings including outpatient clinics, residential care homes, and long-term care facilities. 

Deep Brain Stimulation in Early Stage Parkinson’s Disease: More than one million Americans are living with Parkinson’s disease, a progressive neurodegenerative movement disorder characterized by loss of dopaminergic neurons. Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an approved adjunctive therapy for mid- and advanced stage Parkinson’s disease that improves motor symptoms, quality of life, and activities of daily living while also reducing medication burden and associated complications. Vanderbilt University Medical Center completed the only prospective, randomized clinical trial testing DBS in very early stage Parkinson’s disease. Our ongoing line of research aims to investigate DBS in early stage Parkinson's disease to better understand if this treatment may slow the progression of the disease.

Spasticity in Adults: Spasticity is a form of muscle overactivity, which is often experienced by people with central nervous system illness or injuries. Spasticity can lead to many negative symptoms, such as increased incidence of urinary tract infection, pain and discomfort, and reduced quality of life. Additionally, spasticity may impair activities of daily living, making it difficult to perform care activities for patients who require support. Our current line of research aims to validate the use of newly developed tools to assist with the identification of spasticity, to understand the interaction of spasticity and urinary incontinence, and to improve healthcare policy affecting people living in long-term care facilities.  

TeleHealth: Our current line of TeleHealth research addresses treatment of people with cervical dystonia, spasticity, and headache. We also lead our continuous quality improvement of teleneurology services provided in community based hospitals by measuring physician and patient satisfaction and comparing results to in person care. 

Clinical Research Opportunities: We are accepting applications for undergraduate research roles within our team. Please send your résumé with an accompanying statement of interest to david.charles@vanderbilt.edu

Vanderbilt University has received or currently receives income from grants or contracts with Allergan, Boehringer-Ingelheim, Pharma 2 B, Revance, USWorldMeds, Voyager, DuPont, Elan, Hoffman-LaRoche, Ipsen, Kyowa, Medtronic, Merz, Novartis, and Smith-Kline to support Dr. Charles research efforts. Dr. Charles has received or currently receives income from Allergan, Alliance for Patient Access, Boehringer-Ingelheim, Ipsen, Medtronic, Merz, Mylan-Bertek, Novartis, Ovation, Pfizer, Prestwick, Revance, Schwarz, UCB, USWorldMeds, and Vernalis for consulting services.

Holly Cannon, MSN

Holly
Cannon
MSN
Assistant
Neurology

Holly Cannon is an Advanced Practice Registered Nurse in the Department of Neurology at Vanderbilt University Medical Center, specializing in Neuromuscular, a position she has held since 2019. She is an active member of the American Association of Nurse Practitioners.

Prior to her current role, Holly worked as a Registered Nurse in Vanderbilt’s Neuro Intensive Care Unit and the Neurosurgery Ambulatory Clinic. She also gained several years of nursing experience in the neuroscience field in various institutions before beginning at Vanderbilt in 2015. 

Holly received her Bachelor of Science in Nursing in 2010 from Middle Tennessee State University. While working in the Neuro ICU, she went back to MTSU and earned her Master of Science in Nursing Advanced Practice in 2018. She is a member of AANEM.

Kiersten A. Brown Espaillat, DNP

Kiersten
A.
Brown Espaillat
DNP
Assistant
Neurology
Program Manager
Stroke

Kiersten Brown Espaillat is an Advanced Practice Registered Nurse currently serving as the Stroke Program Manager at Vanderbilt University Medical Center. In her role, which she has held since 2017, she fulfills a variety of educational and administrative duties that elevate stroke patient care, follow-up, and preventions. Dr. Brown Espaillat presents monthly lectures to medical residents, nurses, advanced practice providers, and emergency medical services on topics including anatomy and physiology of stroke, recognition of stroke, and treatment of acute stroke. She has served as an organizer and lecturer for the annual Harold Jobe Bernard Stroke and Neuroscience Symposium since 2012. 

Dr. Brown Espaillat participates in a number of professional organizations and committees, including the American Heart Association Greater Southeast Affiliate Board and related committees, both the Steering and Outreach committees of the EMS Center of Excellence, Sigma Beta Thau among others. She has received recognition for her work on stroke legislation in the state of Tennessee by the American Heart Association. In 2019, she received VUMC’s Jerita Payne Advanced Practice Nurse of the Year Award. 

Dr. Brown Espaillat began her career at VUMC in 2011, first as a Neuroscience Educator then as Stroke Coordinator before moving into her present role. She earned her DNP in 2013 from the University of Tennessee Health Science Center, following her MSN, which she received from the Vanderbilt School of Nursing. She obtained a BS in Education from Vanderbilt University prior to her nursing career. 

Laura Brown-Coulam, PhD

Laura
Brown-Coulam
PhD
Instructor
Clinical Neurology

Dr. Brown joined the Vanderbilt Neurology Department in 2013 in the Division of Cognitive and Behavioral Neurology. As a clinical neuropsychologist, she works with adult patients with known or suspected neurodegenerative conditions and stroke. She provides comprehensive neurocognitive evaluations at the One Hundred Oaks Campus of VUMC.

After earning an undergraduate degree in psychology from Williams College summa cum laude, Dr. Brown worked as a research associate at Massachusetts General Hospital in Boston at the Alzheimer’s Disease Research Center. She then earned her master’s and doctoral degrees in clinical psychology (with specializations in aging and neuropsychology) from Washington University in St. Louis where she was awarded the Olin Fellowship for Women. She completed her clinical internship and post-doctoral fellowship at Brown University Medical School in Providence, Rhode Island. She has been a licensed clinical psychologist since 2005. Since that time, she has practiced in both private and academic hospital settings. 

Dr. Brown is a member of the National Academy of Neuropsychology and the International Neuropsychological Society.

Dr. Brown has been involved in clinical trials investigating treatments for Alzheimer’s disease and Parkinson’s disease. Additionally, some of her research has focused on driving in mild cognitive impairment and dementia.

Kelly M. Brown, MD

Kelly
M.
Brown
MD
Professor of Neurology
Division Chief
Sleep
Vice Chair
Clinical Operations
Executive Medical Director
Neuroscience Patient Care Center

Dr. Brown is a Professor of Neurology at Vanderbilt and the Executive Medical Director of the Neuroscience Patient Care Center for VUMC. Dr. Brown has Certification from the American Board of Psychiatry and Neurology in Sleep Medicine (2011), Neurology (2013), and Epilepsy (2013) and from the American Board of Internal Medicine in Internal Medicine (1999). 

She received her undergraduate degree from Muhlenberg College in Pennsylvania.  She received her Doctor of Medicine from Drexel University, Center City Hahemann Medical Campus in 1996. The following year, she completed her internship at Thomas Jefferson University Medical Center. Subsequently, she completed an Internal Medicine residency at Pennsylvania State Milton S. Hershey Medical Center. She then completed a Neurology residency at Washington University Medical Center in 2002, where she was also Chief Resident. In 2003, she completed a fellowship in Epilepsy, also at Washington University Medical Center, and in 2009, she completed a fellowship in Sleep Medicine at Taylor Hospital in Pennsylvania.

Amy E. Brown, MD, MS

Amy
E.
Brown
MD, MS
Assistant Professor
Movement Disorders Division

Faculty Spotlight

Dr. Brown is a movement disorder specialist who is licensed to practice medicine in Tennessee and Kentucky, and has been a member of the American Board of Psychiatry and Neurology since 2019. She joined Vanderbilt University Medical Center faculty in July 2019 as a postgraduate movement disorders fellowship and has stayed on as an Assistant Professor.  She is the director of the VUMC CurePSP Center of Care.  

Dr. Brown has obtained several honors, including induction to the Gold Humanism Honor Society in 2014 and participating in the American Academy of Neurology (AAN) Palatucci Advocacy Leadership Forum in 2019. She has also advocated for her patients with the AAN Neurology on the Hill and participates with local medical societies.  

Dr. Brown is a Chicago-native who earned a BA in Biology and History in 2009 from Case Western Reserve University (CWRU) in Cleveland, OH. She then completed a Master’s in Science in Biology with a focus on neurobehavior at CWRU in 2011. She attended University of Illinois at Chicago College of Medicine in Chicago, IL, where she earned her MD in 2015. She completed her neurology residency at Loyola University Medical Center, Maywood, IL.  

Dr. Brown is currently leading or involved with several clinical trials to delay disease progression or provide symptomatic improvement of motor and non-motor symptoms for neurodegenerative diseases such as Parkinson’s disease, Multiple Systems Atrophy, Progressive Supranuclear Palsy, Wilson’s disease, and Huntington’s disease.  She oversees several research nurses and coordinators.  

For more on Dr. Brown’s current research, visit the Cognition and Movement Lab page

Jeri Braunlin, DNP, ACNS, BC, NEA, BC, CNRN, RN

Jeri
Lynn Marie
Braunlin
D.N.P.
Assistant
Neurology

Jeri Braunlin is an Advanced Practice Nurse at the Vanderbilt University Medical Center in the Department of Neurology. She is the Program Manager for the C3FIT (Coordinated, Collaborative, Comprehensive, Family-based, Integrated, and Technology-enabled Care) study and works also in the stroke clinic. She is frequently invited to present neuroscience and cerebrovascular disease lectures for both professionals and the general public. She recently spoke at the 2020 International Stroke Conference in Los Angeles and presented “Transitions of Care: Nursing Roles Stroke Central and Stroke Mobile.”

Prior to her appointment at Vanderbilt, Dr. Braunlin served in various clinical and educational roles in other hospital systems. She developed and managed two hospital system stroke programs, served in quality management, and was a member of the Kettering Medical Center IRB for 13 years. Most recently she provided follow-up care in the Stroke Clinic at Miami Valley Hospital in Dayton, Ohio and managed the Neuroscience Stroke Program of research. She is a board-certified Adult Clinical Nurse Specialist (CNS, BC) and Nurse Executive (NEA, BC), in addition to certifications in Neuroscience (CNRN).

Dr. Braunlin received her RN from the Mount Caramel School of Nursing and her BSN from Capital University. She completed her MSN from The Ohio State University College of Nursing, followed by a second Master of Science in Nursing degree from Wright State University College of Nursing in Adult Health. She earned her Doctorate of Nursing in 2017, also from Wright State, with a capstone project entitled, “Feasibility and Accuracy of Predicting Stroke Severity in the Field.”

Francesca Bagnato, MD, PhD

Francesca
Bagnato
MD, PhD
Associate Vice Chair
Research
Associate Professor
Clinical Neurology

Dr. Francesca Bagnato is a dual-board (European and American) neurology certified physician, currently on faculty at Vanderbilt University Medical Center. Dr. Bagnato is a general neurologist with special interest in neuroimmunological conditions. She is licensed to practice medicine in Tennessee and Kentucky. She sees patients with neuroimmunological diseases at the Neuroimmunology Clinic of Vanderbilt University Medical Center as well as the Nashville VA HealthCare system. She joined Vanderbilt in October 2015 after serving as staff scientist at the NIH. She was recruited to establish the neuroimaging program of the neuroimmunology division.

Dr. Bagnato routinely serves Research Advisory Committees such as that of of the Italian MS Society, the British MS Society, the National Institutes of Health, the Veteran Administration, the National Multiple Sclerosis Society, the Canada Foundation for Innovation (Neuroimaging) and Department of Defense. She is a standing member of the Clinical Pilot Research Committee of the National Multiple Sclerosis Society, the TN/KY Healthcare Advisory Committee National Multiple Sclerosis Society (HAC-NMSS) and the National Medical Advisory Committee of the National Multiple Sclerosis Society (NMAC-NMSS). She is an ad hoc member of several NIH Study Sections and the Canada Foundation for Innovation (Neuroimaging). Dr. Bagnato is the Director of Research-MSCoE-East for the Veteran Administration. She is the author of more than 100 publications, has delivered numerous talks around the world and she is a member of the American Academy of Neurology and the American Neurological Association.

Dr. Bagnato has been the recipient of numerous awards including the Special Award for Performance Management Appraisal Program (HHS Employee Performance Plans) of NIH; the NIH-Post Baccalaureate IRTA Committee Award in Recognition of the Outstanding Contributions to the Education and Guidance of Post Baccalaureate Trainers; the NIH-NINDS Merit Award for Mentoring; and the National Multiple Sclerosis Society Healthcare Professional Champion Award for her work in MS Research, Education, and as a Healthcare Provider Serving Those in the Community.

Dr. Bagnato earned a medical degree at the University of Rome La Sapienza in 1996. She accomplished a dual European and American Residency in Neurology, which she completed at the University of Rome La Sapienza and the University of Maryland in Baltimore, MD. She earned a PhD in neuroscience which she completed while performing her studies at the National Institutes of Health, Bethesda, MD in 2006. 

Dr. Bagnato’s lab has two main complementary research goals. First: the lab aims to understand the pathobiology of MS and the substrate of its disability using noninvasive imaging methods such as magnetic resonance imaging (MRI) also coupled with artificial intelligence. Second: the lab aims to identify a surrogate marker of neurodegeneration that can be used as measure of outcome during both natural history and experimental clinical trials, assessing neuroprotection and repair in patients with MS. To this end, a major focus is to identify, characterize and quantify disease mechanisms otherwise hidden on conventional clinical imaging. These pathological processes include microglia activation, myelin and axonal injury. By working in close collaboration with basic scientists and clinicians, our work starts with the histopathological validation of novel MRI methods and ends with the application of these innovative techniques in patients with MS.

Dr. Bagnato’s lab is generously supported by the National Multiple Sclerosis Society the National Institutes of Health, the Veteran Administration and the Voros Innovation and Impact Fund generously created in support of her lab.